A paper published this month in the Proceedings of the National Academy of Sciences reports that psychedelics disrupt hierarchical cortical propagations in the default mode network, and that the disruption appears in both humans and mice. The work, by Adam Pines and colleagues, is a circuit-level neuroscience finding, not a clinical one, and the distinction is the entire reason it is worth attention. It does not show that psychedelics treat any condition. It strengthens the case that a specific, long-hypothesized brain effect is real and conserved across species rather than an artifact of human psychology or the limits of human brain imaging.
What the finding is
The cortex is organized as a rough hierarchy. Information flows from lower-order sensory regions, the parts that handle vision and touch, upward through association areas to the highest-order networks, with the default mode network sitting near the top. That flow is not random. Activity propagates across the hierarchy in structured, directional patterns. The default mode network, which is associated with self-referential thought and the sense of self, is the apex of that arrangement, and a standing hypothesis in psychedelic neuroscience holds that these drugs work in part by flattening or compressing this functional hierarchy, with the strongest effects concentrated in the default mode network.
The Pines paper adds a specific and demanding piece of evidence to that hypothesis. It reports that psychedelics disrupt the ordered, hierarchical propagation of activity in the default mode network, and that the same disruption signature is present in mice as in humans. The headline is not that the default mode network changes under psychedelics, which has been shown many times. It is that the disruption takes a particular hierarchical form and that it crosses the species boundary.
Why cross-species convergence is the point
Human psychedelic neuroscience carries a built-in vulnerability. The most striking findings come from people who know they have taken a powerful drug, in carefully managed settings, reporting profound subjective experiences, and measured with functional imaging that is coarse in both space and time. A skeptic can reasonably ask how much of a reported brain change reflects the drug acting on a circuit, and how much reflects expectancy, the setting, the subjective experience itself, or the resolution of the instrument. The default mode network’s association with the sense of self makes this worse, because it is exactly the kind of result that invites a story about phenomenology rather than physiology.
Mice remove most of those confounds. A mouse has no expectation about a psychedelic, no set and setting, no narrative about ego dissolution. In animals, researchers can record neural activity at far higher resolution than human imaging allows and can manipulate circuits causally. Finding the same hierarchical-propagation disruption in mice that is seen in humans means the effect is a property of the drug acting on conserved circuitry, not a byproduct of human psychology or a limitation of human scanners. The field already had strong but separate results on each side: human work showing psychedelics desynchronize brain networks most strongly in the default mode network, and rodent work showing they rewire the connectivity of the mouse default mode network homolog. The contribution here is a shared measure that bridges the two, which is harder to wave away than either alone.
What it means for mechanism research
For people trying to understand how psychedelics act, the practical value is a conserved, manipulable handle on the mechanism. If the same hierarchical-propagation disruption occurs in mice, then the mouse becomes a legitimate model for dissecting the circuitry, the receptors, and the causal sequence behind it, in ways that are impossible in humans. That moves the default mode network account from a description of what happens in the human brain toward a mechanism that can be tested, perturbed, and either confirmed or falsified in an animal where the experimenter controls the variables. Anchoring a human imaging phenomenon to conserved circuitry is the step that turns a correlation into a research program.
What it means for regulatory confidence
Regulators have had reason to be wary of psychedelic mechanism claims, in part because the effects are so entangled with subjective experience that it is hard to separate the drug from the trip. A species-independent circuit signature offers a more objective foundation. It does not tell a regulator that a drug works, but it does support the more basic claim that there is a definable, biologically grounded mechanism rather than a cloud of subjective effects. For a field whose credibility took damage when the FDA rejected the Lykos MDMA application over trial-conduct and interpretability concerns, evidence that the core mechanism is real and conserved is useful to the scientific case, even though it is upstream of any efficacy question.
What it means for trial design
The most concrete potential application is a biomarker. If disruption of hierarchical cortical propagation in the default mode network is a reliable, measurable signature of a psychedelic engaging its target, it could serve as an objective readout of target engagement, a way to confirm the drug did what it is supposed to do in the brain without relying on the patient’s report. That matters for the problem the desk has flagged repeatedly in this drug class: functional unblinding, where participants and raters can tell who received an active psychedelic, which inflates apparent effects. A target-engagement measure that does not depend on the subject knowing they were dosed would be a real methodological tool. The Pines finding does not deliver that biomarker, but it is the kind of result a validated biomarker would be built on.
The caveat that has to lead, not trail
None of this establishes clinical benefit, and it is important not to let a stronger mechanism story masquerade as efficacy evidence. Disrupting hierarchical propagation in the default mode network is target engagement. It is a statement that the drug does something specific and conserved to a brain circuit. It is not a statement that doing so helps a patient with depression, addiction, or anything else. Plenty of interventions alter the default mode network, including the disorders themselves and ordinary anesthetics, without therapeutic value. The acute circuit disruption this paper describes is also distinct from the durable plasticity, the persistent connectivity changes and synaptic remodeling, that the field believes underlies whatever lasting benefit psychedelics produce. The leap from the drug reliably does this to the brain across species to this is why, or whether, it treats illness remains unmade, and this paper does not make it.
The honest framing is that the Pines work makes default mode network disruption much harder to dismiss as a quirk of human phenomenology, and hands researchers a conserved system in which to study it. That is genuine progress on the question of how these drugs act on the brain. It is not progress on the separate and harder question of whether acting on the brain that way makes anyone better, and keeping those two questions apart is the whole discipline of reading a paper like this correctly.